Literature DB >> 26452665

RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer.

Laura A Tookman1, Ashley K Browne1, Claire M Connell1, Gemma Bridge1, Carin K Ingemarsdotter1, Suzanne Dowson2, Atsushi Shibata3, Michelle Lockley1, Sarah A Martin1, Iain A McNeish4.   

Abstract

UNLABELLED: Homologous recombination (HR) function is critically important in high-grade serous ovarian cancer (HGSOC). HGSOC with intact HR has a worse prognosis and is less likely to respond to platinum chemotherapy and PARP inhibitors. Oncolytic adenovirus, a novel therapy for human malignancies, stimulates a potent DNA damage response that influences overall antitumor activity. Here, the importance of HR was investigated by determining the efficacy of adenovirus type 5 (Ad5) vectors in ovarian cancer. Using matched BRCA2-mutant and wild-type HGSOC cells, it was demonstrated that intact HR function promotes viral DNA replication and augments overall efficacy, without influencing viral DNA processing. These data were confirmed in a wider panel of HR competent and defective ovarian cancer lines. Mechanistically, both BRCA2 and RAD51 localize to viral replication centers within the infected cell nucleus and that RAD51 localization occurs independently of BRCA2. In addition, a direct interaction was identified between RAD51 and adenovirus E2 DNA binding protein. Finally, using functional assays of HR competence, despite inducing degradation of MRE11, Ad5 infection does not alter cellular ability to repair DNA double-strand break damage via HR. These data reveal that Ad5 redistributes critical HR components to viral replication centers and enhances cytotoxicity. IMPLICATIONS: Oncolytic adenoviral therapy may be most clinically relevant in tumors with intact HR function. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26452665      PMCID: PMC4716290          DOI: 10.1158/1541-7786.MCR-15-0188-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  47 in total

1.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

Authors:  A J Pierce; R D Johnson; L H Thompson; M Jasin
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

2.  Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex.

Authors:  E Querido; P Blanchette; Q Yan; T Kamura; M Morrison; D Boivin; W G Kaelin; R C Conaway; J W Conaway; P E Branton
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

3.  Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.

Authors:  Carin K Ingemarsdotter; Laura A Tookman; Ashley Browne; Katrina Pirlo; Rosalind Cutts; Claude Chelela; Karisma F Khurrum; Elaine Y L Leung; Suzanne Dowson; Lee Webber; Iftekhar Khan; Darren Ennis; Nelofer Syed; Tim R Crook; James D Brenton; Michelle Lockley; Iain A McNeish
Journal:  Mol Oncol       Date:  2014-12-29       Impact factor: 6.603

4.  Monitoring I-SceI-induced double-strand break repair in DT40 cells.

Authors:  David du Plessis; Julian E Sale
Journal:  Methods Mol Biol       Date:  2012

5.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

Authors:  J Fueyo; C Gomez-Manzano; R Alemany; P S Lee; T J McDonnell; P Mitlianga; Y X Shi; V A Levin; W K Yung; A P Kyritsis
Journal:  Oncogene       Date:  2000-01-06       Impact factor: 9.867

6.  Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase.

Authors:  J Boyer; K Rohleder; G Ketner
Journal:  Virology       Date:  1999-10-25       Impact factor: 3.616

7.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Authors:  C Heise; T Hermiston; L Johnson; G Brooks; A Sampson-Johannes; A Williams; L Hawkins; D Kirn
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

8.  Catalytic and noncatalytic roles of the CtIP endonuclease in double-strand break end resection.

Authors:  Nodar Makharashvili; Anthony T Tubbs; Soo-Hyun Yang; Hailong Wang; Olivia Barton; Yi Zhou; Rajashree A Deshpande; Ji-Hoon Lee; Markus Lobrich; Barry P Sleckman; Xiaohua Wu; Tanya T Paull
Journal:  Mol Cell       Date:  2014-05-15       Impact factor: 17.970

9.  Evaluating cell lines as tumour models by comparison of genomic profiles.

Authors:  Silvia Domcke; Rileen Sinha; Douglas A Levine; Chris Sander; Nikolaus Schultz
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  SV40 utilizes ATM kinase activity to prevent non-homologous end joining of broken viral DNA replication products.

Authors:  Gregory A Sowd; Dviti Mody; Joshua Eggold; David Cortez; Katherine L Friedman; Ellen Fanning
Journal:  PLoS Pathog       Date:  2014-12-04       Impact factor: 6.823

View more
  11 in total

Review 1.  The MRE11-RAD50-NBS1 Complex Conducts the Orchestration of Damage Signaling and Outcomes to Stress in DNA Replication and Repair.

Authors:  Aleem Syed; John A Tainer
Journal:  Annu Rev Biochem       Date:  2018-04-25       Impact factor: 23.643

Review 2.  Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.

Authors:  Sean M O'Cathail; Tzveta D Pokrovska; Timothy S Maughan; Kerry D Fisher; Leonard W Seymour; Maria A Hawkins
Journal:  Front Oncol       Date:  2017-07-24       Impact factor: 6.244

3.  Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers.

Authors:  Yuqiu Ge; Yunyan Wang; Wei Shao; Jing Jin; Mulong Du; Gaoxiang Ma; Haiyan Chu; Meilin Wang; Zhengdong Zhang
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

4.  Cell-Surface Integrins and CAR Are Both Essential for Adenovirus Type 5 Transduction of Canine Cells of Lymphocytic Origin.

Authors:  Payal Agarwal; Elizabeth A Gammon; Abdul Mohin Sajib; Maninder Sandey; Bruce F Smith
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

5.  RIPK3 promotes adenovirus type 5 activity.

Authors:  Melanie Weigert; Alex Binks; Suzanne Dowson; Elaine Y L Leung; Dimitris Athineos; Xinzi Yu; Margaret Mullin; Josephine B Walton; Clare Orange; Darren Ennis; Karen Blyth; Stephen W G Tait; Iain A McNeish
Journal:  Cell Death Dis       Date:  2017-12-13       Impact factor: 8.469

6.  Bacterial RecA Protein Promotes Adenoviral Recombination during In Vitro Infection.

Authors:  Jeong Yoon Lee; Ji Sun Lee; Emma C Materne; Rahul Rajala; Ashrafali M Ismail; Donald Seto; David W Dyer; Jaya Rajaiya; James Chodosh
Journal:  mSphere       Date:  2018-06-20       Impact factor: 4.389

Review 7.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

8.  External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.

Authors:  Tzveta D Pokrovska; Egon J Jacobus; Rathi Puliyadi; Remko Prevo; Sally Frost; Arthur Dyer; Richard Baugh; Gonzalo Rodriguez-Berriguete; Kerry Fisher; Giovanna Granata; Katharine Herbert; William K Taverner; Brian R Champion; Geoff S Higgins; Len W Seymour; Janet Lei-Rossmann
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

Review 9.  Adenoviromics: Mining the Human Adenovirus Species D Genome.

Authors:  Ashrafali M Ismail; Ji Sun Lee; Jeong Yoon Lee; Gurdeep Singh; David W Dyer; Donald Seto; James Chodosh; Jaya Rajaiya
Journal:  Front Microbiol       Date:  2018-09-11       Impact factor: 5.640

10.  Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment.

Authors:  Er Yue; Guangchao Yang; Yuanfei Yao; Guangyu Wang; Atish Mohanty; Fang Fan; Ling Zhao; Yanqiao Zhang; Tamara Mirzapoiazova; Tonya C Walser; Lorna Rodriguez-Rodriguez; Yuman Fong; Ravi Salgia; Edward Wenge Wang
Journal:  Cancers (Basel)       Date:  2021-08-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.